Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
Follow-Up Questions
¿Quién es el CEO de Omnimmune Holdings Inc?
Travis McPhee es el Chief Executive Officer de Omnimmune Holdings Inc, se unió a la empresa desde 2007.
¿Qué tal es el rendimiento del precio de la acción OMMH?
El precio actual de OMMH es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Omnimmune Holdings Inc?
Omnimmune Holdings Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Omnimmune Holdings Inc?
La capitalización bursátil actual de Omnimmune Holdings Inc es $0
